Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Actuate Therapeutics
Biotech
Actuate is latest biotech on Nasdaq after $22.4M IPO
Actuate Therapeutics became the latest biotech to join the Nasdaq this week with a scaled-back IPO that brought in $22.4 million.
James Waldron
Aug 15, 2024 4:29am
Cancer-focused Actuate makes 2nd tweak to IPO plans in a week
Jul 24, 2024 4:37am
Actuate halves IPO to $22M, scales back clinical plans
Jul 22, 2024 4:54am
Actuate unveils modest $50M IPO to fund cancer drug trials
Jul 17, 2024 4:45am
Clinical-stage cancer biotech Actuate latest to eye summer IPO
May 28, 2024 9:45am
Actuate raises $22M to expand GSK-3β cancer trial
May 17, 2019 9:14am